Trader: Low Volume ...
Health Care: Drugs
A.P. Pharma Inc. (APPA: OTC)
$0.58 0.00 | 0.00%
06/04/12 - 10:32 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.58 |
| 52 Week High | 0.58 |
| 52 Week Low | 0.10 |
| Avg. Daily Vol. (Mil) | 0.06 |
| Beta (3 year) | -0.07 |
| Share Related Items | |
| Mkt Cap (Mil) | 115.03 |
| Shares Out (Mil) | 200.05 |
| Float (Mil) | 91.07 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.00 |
| Current Ratio | 4.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 458.27 |
| Price/Book | 9.89 |
| Price/Cash Flow | -7.70 |
| Per Share Data | |
| Earnings | -0.11 |
| Sales | 0.00 |
| Book Value | 0.06 |
| Cash Flow | -0.07 |
| Business Summary | |
|---|---|
| A.P. Pharma, Inc. is a specialty pharmaceutical company, which is developing products using its proprietary Biochronomer(tm) polymer-based drug delivery technology. | |
| General Information | |
| 123 Saginaw Drive
Redwood City, CA 94063 |
|
| www.advancedpolymer.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 19 | |
| CEO: John B. Whelan | |
| Short Interest | |
| Current Month (Mil) | 0.27 |
| Previous Month (Mil) | 0.27 |
| Short Interest Ratio (Days) | 1.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -102.10 |
| Return on Investments | -131.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with APPA
- Portfolio NameUser Type
- UserMy Folio
- Userwatchlist1
- UserMARK 1 C
- ContributorBarron's Insider Purchases ...
- UserSUPRATRADE-2709091838
- UserLatest Activist Filings 2-2...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- UserBarron's Insider Purchases ...
Latest APPA Headlines from TheStreet
- Ambac Financial, QAD: Early Volume Plays 05.18.10 | 08:05 am
- A.P. Pharma, Netlist: Early Volume Plays 03.19.10 | 10:03 am
- Biotech Stock Mailbag: Sequenom 03.12.10 | 07:03 am
- Latest News in Activist Investing 02.26.09 | 11:02 am
- Insider Action: Trading Level 3 10.03.08 | 12:10 pm
- Monday's Small-Cap Winners & Losers 06.25.07 | 04:06 pm
- Thursday's Health Winners & Losers 12.21.06 | 01:12 pm
- Monday's Small-Cap Winners & Losers 10.02.06 | 03:10 pm
Press Releases for APPA
- A.P. Pharma Announces Study Finding Continuous Exposure To A 5-HT3 Antagonist Using APF530 Provides Better Emetic Control - Business Wire 05.31.12 | 08:05 am
- A.P. Pharma Announces First Quarter 2012 Financial Results And Recent Corporate Progress - Business Wire 05.10.12 | 08:05 am
- A.P. Pharma Announces Third Quarter 2011 Financial Results And Recent Corporate Progress - Business Wire 11.07.11 | 08:11 am
- LifeSci Advisors Announces Investment Opinion On A.P. Pharma Inc. - Business Wire 08.29.11 | 01:08 pm
- A.P. Pharma Announces Second Quarter 2011 Financial Results And Reports On Recent Corporate Progress - Business Wire 08.08.11 | 08:08 am
- A.P. Pharma To Raise $24 Million In Private Placement Of Common Stock And Warrants - Business Wire 06.29.11 | 08:06 am
- A.P. Pharma Announces First Quarter 2011 Financial Results And Recent Corporate Progress - Business Wire 05.16.11 | 08:05 am
- A.P. Pharma Announces Financing Of Up To $4.5 Million And Names CEO And COO - Business Wire 04.25.11 | 08:04 am
- A.P. Pharma Provides Regulatory Update On APF530 NDA - Business Wire 04.25.11 | 08:04 am
- A.P. Pharma Announces Transfer To OTCQB - Business Wire 03.31.11 | 06:03 am
Partner Headlines for APPA
- Mannkind Slashes Staff: Biotech's Latest Tribulations - Seeking Alpha 02.13.11 | 08:02 am
- UPDATE 3-FDA denies approval of AP Pharma nausea drug; shrs sink - Reuters 03.19.10 | 12:03 pm
